Last reviewed · How we verify
vitagen plus hyruan
Vitagen Plus Hyruan is a combination product that delivers hyaluronic acid and bioactive compounds to support joint lubrication and tissue hydration.
Vitagen Plus Hyruan is a combination product that delivers hyaluronic acid and bioactive compounds to support joint lubrication and tissue hydration. Used for Osteoarthritis of the knee, Joint pain and stiffness associated with degenerative joint disease.
At a glance
| Generic name | vitagen plus hyruan |
|---|---|
| Also known as | dextrose plus hyaluronic acid |
| Sponsor | Taipei Medical University |
| Drug class | Viscosupplement / Joint lubricant |
| Target | Hyaluronic acid receptor (CD44); joint synovial fluid |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
The product combines hyaluronic acid (a natural component of synovial fluid) with additional bioactive ingredients to enhance joint lubrication, reduce friction, and promote tissue hydration. Hyaluronic acid acts as a viscoelastic agent that improves shock absorption and joint mobility while supporting the structural integrity of cartilage and connective tissues.
Approved indications
- Osteoarthritis of the knee
- Joint pain and stiffness associated with degenerative joint disease
Common side effects
- Injection site pain or swelling
- Transient joint effusion
- Local inflammation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vitagen plus hyruan CI brief — competitive landscape report
- vitagen plus hyruan updates RSS · CI watch RSS
- Taipei Medical University portfolio CI